Diagnostic US for Reduction of Benign Breast Biopsies Using US-guided Optical Tomography

Overview

Ultrasound-guided diffuse optical tomography (DOT) has demonstrated its potential role in differentiating malignant and benign breast abnormalities and in predicting and monitoring the neoadjuvant chemotherapy (NAC) response of breast cancer. This unique approach employs a commercial ultrasound (US) transducer and near infrared (NIR) optical imaging sensors mounted on a hand-held US probe. The co-registered US is used for lesion localization, and optical sensors are used for imaging tumor related vascularity.

Full Title of Study: “Improving Diagnostic US for Reduction of Benign Breast Biopsies Using US-guided Optical Tomography”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 30, 2024

Interventions

  • Device: Hand-held hybrid probe
    • Consists of a commercially available US transducer located in the middle and near-infrared source and detector optical fibers distributed at the periphery

Arms, Groups and Cohorts

  • Experimental: Phase I – Training Set
    • 20 patients will be recruited to undergo US-DOT and CEM to allow for training study readers in assessing US-DOT data, intra-observer variability and to assess inter-observer variability in the assessment of US-DOT data A hand-held hybrid probe will be used for the scans
  • Experimental: Phase 2: Prospective Trial
    • US-DOT (US/NIR) Imaging Exam Breast biopsy or FNA performed (standard of care) A hand-held hybrid probe will be used for the scans

Clinical Trial Outcome Measures

Primary Measures

  • Impact of US-guided DOT on the potential reduction of benign biopsies as measured by comparing the specificity of conventional imaging (CI = US +/- Mammography) alone versus CI & US-DOT
    • Time Frame: Completion of enrollment for all patients (estimated to be 87 months)
    • -BI-RADS scores without and then with optical data will be rendered by study radiologists. Radiologists will be blinded to the biopsy exam and pathology outcomes. Optical data including total Hemoglobin concentration will be provided by the bioengineering team. Specificity will be calculated as the proportion of subjects with a non- suspicious assessment, i.e. BIRADS 2 ‘benign’ or BIRADS 3 ‘probably benign’, divided by the denominator of subjects with no cancer demonstrated at biopsy. US-guided core biopsy results and subsequent surgical pathology (if present) will be entered by the study pathologist.
  • Impact of US-guided DOT as an adjunct to conventional breast imaging on maintaining high sensitivity as measured by comparing the false negative rate of conventional imaging (CI=US +/- Mammography) alone versus CI & US-DOT
    • Time Frame: Completion of enrollment for all patients (estimated to be 87 months)
    • -BI-RADS scores without and then with optical data will be rendered by study radiologists. Radiologists will be blinded to the biopsy exam and pathology outcomes. Optical data including total Hemoglobin concentration will be provided by the bioengineering team. The False Negative Rate will be calculated as the proportion of subjects with a non-suspicious assessment i.e. BIRADS 2 ‘benign’ or BIRADS 3 ‘probably benign’, who have cancer (defined as Invasive cancer or Ductal Carcinoma In Situ) demonstrated at biopsy divided by the denominator of all subjects with cancer. US-guided core biopsy results and subsequent surgical pathology (if present) will be entered by the study pathologist

Participating in This Clinical Trial

Inclusion Criteria

  • Female subjects ≥ 18 years old with ultrasound visible breast abnormalities (BI-RADS 3*, 4A, 4B, 4C, and 5) referred for ultrasound-guided core needle biopsy or fine needle aspiration *note that while a BI-RADS 3 assessment is probably benign, a subset of patients with this assessment choose to undergo biopsy rather than follow up imaging). – Willing and able to provide informed consent Exclusion Criteria:

  • Lesions located in the darkly pigmented nipple-areolar complex area – Subjects with breast implants – Abnormality in the mirror image location of the contralateral breast. – Additional abnormalities in the same region of the breast that would be included in US-guided DOT imaging of the abnormality undergoing biopsy – Previous breast irradiation of the mirror image location of the contralateral breast – Lesions located at previous biopsy sites when biopsy occurred within the last six months. – Small lesions of less than 1 cm located at skin or close to the skin – Pregnancy – Superficial abnormalities located entirely within (i.e. less than) 5mm of the overlying skin

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Washington University School of Medicine
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Debbie Bennett, M.D., Principal Investigator, Washington University School of Medicine
  • Overall Contact(s)
    • Debbie Bennett, M.D., 314-454-7696, debbie.bennett@wustl.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.